bannerhome
 
 

Pipeline

PDS Biotech’s infectious disease pipeline combines the Infectimune™ platform technology with pathogen-specific antigens in the development of preventive infectious disease vaccines.


ProductsIndicationCombinationPCP1P2P3RPARTNER(S)
Infectious Disease
PDS0201
(M-tuberculosis)
Prevention of tuberculosis  
   
image002 

PDS0201

Product information
PDS0201 is a novel investigational tuberculosis vaccine that generates broad and robust antibody and T cell responses that provide durable protection against bacillus Mycobacterium tuberculosis (M. tuberculosis). PDS0202 is given as a single dose by intramuscular injection and is being developed to provide robust and durable protection against tuberculosis.

Disease state
Tuberculosis (TB) is the leading cause of death from a single infectious agent and is caused by the bacillus Mycobacterium tuberculosis, which is spread when people who are sick with TB expel bacteria into the air. About a quarter of the world’s population is infected with M. tuberculosis and thus at risk of developing TB disease. It has been reported that a total of 1.5 million people died from TB in 2018. Worldwide, TB is one of the top 10 causes of death and the leading cause from a single infectious agent (above HIV/AIDS).

Development status
PDS0201 is currently in pre-clinical development.

PDS0202
(influenza)
Universal prevention of influenza  
   
niaid 

PDS0202

Product information
PDS0202 is a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide durable protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. PDS0202 is given as a single dose by intramuscular injection and generates robust and durable protection against multiple strains of the flu in preclinical studies.

Disease state
Influenza or flu is a contagious respiratory illness caused by highly variable and constantly evolving influenza viruses that infect the nose, throat, and sometimes the lungs. It can cause mild to severe illness and can result in death, particularly in the very young and elderly. According to the World Health Organization, influenza is estimated to result in about 3 to 5 million cases of severe illness, and about 290,000 to 650,000 respiratory deaths globally each year. There are several types of seasonal influenza viruses, which cause seasonal epidemics and emerging pandemics. A universal flu vaccine would provide robust, long-lasting protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu.

Development status
PDS0202 is currently in pre-clinical development.

PDS0203
(SARS-CoV-2)
Prevention of COVID-19  
   
 

PDS0203

Product information
PDS0203 is a novel investigational COVID-19 vaccine that generates broad and robust antibody and T cell responses that provide durable protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). PDS0203 is given as a single dose by intramuscular injection and generates robust and durable protection against COVID-19 in preclinical studies.

Disease state
In January of 2020 the world saw the emergence of the COVID-19 outbreak caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The World Health Organization (WHO) declared COVID-19 a global health emergency in January of 2020. Within three months of initial discovery COVID-19 was declared a global pandemic, reflecting alarming levels of spread and severity and resulting in unprecedented action by local and national governments to restrict the movement of citizens to contain the spread.

Development status
PDS0203 is currently in pre-clinical development.

PDS Biotech Funded funded   Partner Co-Funded parfunded

 

Receive Email Alerts

Join our mailing list to receive the latest news and updates from our team.

Sign up

pdf